Identifying high-probability, high-profit opportunities among small-cap stocks all over the world is the reason for Wall Street Daily’s existence.
That’s a big universe of companies to track.
Further complicating the project is the fact that many are cutting-edge innovators in esoteric, highly sophisticated technologies.
So we think you’re likely to benefit from a little assistance in separating the mere great ideas from actual solutions to real-world problems.
The way we get to what’s real – technologies that translate into revenue, earnings and share price growth – is a process that starts with “primary due diligence.”
Yes, that’s a fancy phrase that basically means research. But it’s a very specific type of research that’s crucial to establishing a competitive advantage in the market and making profitable investments.
In addition to reading 10-Ks, 10-Qs, conference call transcripts, and roadshow presentations, we like to go to the sources ourselves. We make visits to company headquarters, talk with executives, and observe day-to-day operations.
This also means picking up the phone and speaking with customers or related parties that have some insights into a company. Insights that wouldn’t be available anywhere else.
And it involves identifying other sources – including academic and industry-specific journals and blogs – that provide in-depth coverage of stuff like nanotechnology and the biomedical revolution.
We’re still in the “tell” phase of our research, identifying the startups and getting a grip on their specific contributions to a technology that may, as American futurist Ray Kurzweil suggests, allow us to increase life spans to the degree that we may eventually be able to live as long as we want.
Of course, an infinite existence will require a lot of money.
And we hope you’ll someday see significant profits from companies that are already building the nanobot factories that will make immortality possible.
Nanotechnology, nanorobotics, and nanobots will one day allow us to “transcend the limitations of biology,” helping us fight pathogens as well as cancers.
“You and I are gonna live forever.”
The cool thing? The future is, well… now.
(And it was foretold by the well-received 1966 cinema classic Fantastic Voyage, with Raquel Welch and Donald Pleasence, and the 1987 remake Innerspace, with Dennis Quaid, Martin Short and Meg Ryan.)
We’re already making tiny biological machines – “designer microbes” or “genetically modified bacteria” – that are helping to make pharmaceuticals and “sweat” biofuels.
Pretty soon, nanobots will clean up pollution and perform microsurgery.
According to Kurzweil, “What is now a trickle of clinical applications will be a flood in 10 years, when these technologies are again 1,000 times more powerful. They will be 1 million times more powerful than they are today in 20 years.”
Is it really only a matter of time until technology overcomes age-related diseases?
“We can rebuild him. We have the technology. We can make him better than he was. Better, stronger, faster.”
If we’re to see the day when technology adds more than a year to our life expectancy every year – that, folks, is what we call “immortality” – it’s possible that one, two, or all three of the following companies will be among the innovators that make it happen.
All three “synthetic biology” companies are building factories to produce designer organisms as the race to commercialize the ones that provide real-world solutions to real-world problems accelerates.
They’re all privately held right now.
~ Zymergen: Founded in 2013, Zymergen is using “big data” and robotics to evaluate thousands of microbe strains. Its calling card is cool, way-out-there technology for DNA-manipulating robots.
According to Zymergen CEO Josh Hoffman: “A lot of lab automation is built with [testing] in mind. What we do that’s unusual – and as far as we know, we’re the only people in the world to do it – is we use robots to assemble all the DNA, put it together and stick it across the cell membrane and into the bug itself. And then it integrates.”
One expert in the bio lab field, IndieBio partner Ryan Bethencourt, said that Zymergen “has the potential to become the Google of strain optimization.”
~ Ginkgo Bioworks: The Boston-based firm, founded in 2008, is using automation to manipulate yeast DNA to make fragrances.
Its organism engineering foundry – the world’s first – integrates advanced software, robots and biology to design, build and test bespoke synthetic organisms.
Ginkgo is working on more than 20 organisms for customers looking for a yeast strain for animal feed, a new sweetener for beverages, and an organic pesticide.
~ Synthace: The company’s Antha factory combines expertise in biology, chemistry and computer engineering, anticipating a future in which designing synthetic organisms is as simple as writing code.
The London-based company was recently named a World Economic Forum Technology Pioneer – an acknowledgment that it’s one of the world’s most innovative companies.
Antha’s open-source operating system for building synthetic organisms should drive rapid productivity growth for bioengineers.
And that’s how Kurzweil’s vision of the future will come to fruition.